Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

BLTE

Belite Bio Inc ADR

Last Close
154.74
Oct 30 • 3:59 PM ET Dollar change+4.46 Percentage change(2.97%)
Aftermarket Close
154.74
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Mid NASD
Peers: KOD OCGN ANNX OCUL IRD EYPT REGN OCS MGTX RGNX
 | Held by: SPEM APIE ONEQ GXC BBC EHLS MSSM TNXT
Scroll to Statements
Index
-
Market Cap
6.23B
Enterprise Value
5.95B
Income
-102.36M
Sales
0.00M
Book/sh
19.28
Cash/sh
6.95
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
41
IPO
Apr 29, 2022
P/E
-
Forward P/E
81.44
PEG
-
P/S
-
P/B
8.02
P/C
22.26
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
50.02
Current Ratio
50.02
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-2.73
EPS next Y
1.90
EPS next Q
-0.79
EPS this Y
-37.69%
EPS next Y
159.74%
EPS next 5Y
-
EPS past 3/5Y
-54.04% -549.64%
Sales past 3/5Y
- -
EPS Y/Y TTM
-76.46%
Sales Y/Y TTM
-
EPS Q/Q
-41.19%
Sales Q/Q
-
Earnings
Aug 13 BMO
EPS/Sales Surpr.
9.89% -
Insider Own
1.80%
Insider Trans
-21.26%
Inst Own
22.24%
Inst Trans
0.72%
ROA
-21.60%
ROE
-22.10%
ROIC
-13.28%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
2.08%
SMA50
-4.17%
SMA200
-3.51%
Trades
Shs Outstand
40.27M
Shs Float
39.55M
Short Float
3.20%
Short Ratio
7.10
Short Interest
1.27M
52W High
200.00 -22.63%
52W Low
95.29 62.39%
Volatility
4.13% 3.90%
ATR (14)
6.18
RSI (14)
50.26
Beta
-1.23
Rel Volume
1.32
Avg Volume
178.40K
Volume
234,905
Perf Week
5.03%
Perf Month
-5.06%
Perf Quarter
-0.03%
Perf Half Y
-0.07%
Perf YTD
-3.26%
Perf Year
57.74%
Perf 3Y
305.18%
Perf 5Y
-
Perf 10Y
-
Recom
1.00
Target Price
227.44
Prev Close
150.28
Price
154.74
Change %
2.97%
Consensus
Strong Buy
Avg. Price Target
$227.44
Implied Upside
+47.0%
Analysts9incl. previous ratings
Rating Distribution9 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 04, 2026Initiated
CCanaccord Genuity
Buy$303+95.8%
Jan 26, 2026Initiated
BAC logoBBofA Securities
Buy$195+26.0%
Jan 06, 2026Initiated
MS logoMMorgan Stanley
Overweight$191+23.4%
Dec 02, 2025Upgrade
MFG logoMMizuho
Neutral → Outperform$194+25.4%
Nov 24, 2025Resumed
CCantor Fitzgerald
Overweight$154-0.5%
Nov 20, 2025Initiated
MFG logoMMizuho
Neutral$105-32.1%
Dec 14, 2023Initiated
MMaxim Group
Buy$60-61.2%
Jul 28, 2023Initiated
CCantor Fitzgerald
Overweight$43-72.2%
Jul 26, 2023Initiated
SSVB Securities
Outperform$25-83.8%
Aug 01, 2022Initiated
HH.C. Wainwright
Buy$58-62.5%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scholl Hendrik PeterChief Medical OfficerOct 01 '26Sale165.3250082,65914,500Oct 05 07:27 PM
Hendrik Peter SchollOfficerOct 01 '26Proposed Sale169.824,000679,280Oct 01 06:04 PM
Lin Yu-HsinChief Executive OfficerSep 04 '26Sale187.7174,43513,972,06396,134Sep 09 07:39 PM
Lin Yu-HsinChief Executive OfficerSep 08 '26Sale196.5626,0005,110,48670,134Sep 09 07:39 PM
Chuang Hao-YuanChief Financial OfficerSep 04 '26Sale187.6449,4339,275,38944,000Sep 09 07:38 PM
Chuang Hao-YuanChief Financial OfficerSep 08 '26Sale196.4217,9623,528,13926,038Sep 09 07:38 PM
Chuang Hao-YuanChief Financial OfficerAug 12 '26Sale180.3536766,18793,433Aug 14 06:10 AM
Lin Yu-HsinChief Executive OfficerAug 12 '26Sale180.3536565,827170,569Aug 14 06:10 AM
Yu-Hsin LinCEO, ChairmanAug 12 '26Proposed Sale177.58126,80022,517,144Aug 12 05:13 PM
Hao-Yuan ChuangOfficer, DirectorAug 12 '26Proposed Sale177.5893,80016,657,004Aug 12 05:12 PM
Scholl Hendrik PeterChief Medical OfficerJun 18 '26Sale145.2410,0001,452,43515,000Jun 22 06:05 AM
Dr. Hendrick P. SchollAffiliateJun 18 '26Proposed Sale148.3410,0001,483,400Jun 18 04:27 PM
Scholl Hendrik PeterChief Medical OfficerJun 16 '26Sale140.5710,0001,405,72925,000Jun 17 06:03 AM
Dr. Hendrick P. SchollAffiliateJun 16 '26Proposed Sale144.2410,0001,442,400Jun 16 07:10 PM
MATA NATHAN L.Chief Scientific OfficerMay 07 '26Sale153.21666102,0390May 08 04:45 PM
MATA NATHAN L.Chief Scientific OfficerMay 06 '26Sale153.841,000153,839666May 07 04:15 PM
MATA NATHAN L.Chief Scientific OfficerMay 05 '26Sale155.501,000155,5021,666May 06 04:15 PM
MATA NATHAN L.Chief Scientific OfficerMay 04 '26Sale155.641,000155,6362,666May 05 04:15 PM
MATA NATHAN L.Chief Scientific OfficerMay 01 '26Sale155.781,000155,7783,666May 04 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 30 '26Sale156.971,000156,9734,666May 01 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 29 '26Sale155.821,000155,8175,666Apr 30 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 28 '26Sale159.161,000159,1626,666Apr 29 04:32 PM
MATA NATHAN L.Chief Scientific OfficerApr 27 '26Sale162.641,000162,6417,666Apr 28 04:28 PM
MATA NATHAN L.Chief Scientific OfficerApr 24 '26Sale159.561,000159,5568,666Apr 27 04:52 PM
MATA NATHAN L.Chief Scientific OfficerApr 23 '26Sale166.281,000166,2849,666Apr 24 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 22 '26Sale170.381,000170,38410,666Apr 23 04:19 PM
MATA NATHAN L.Chief Scientific OfficerApr 21 '26Sale166.001,000166,00011,666Apr 22 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 20 '26Sale163.591,000163,59512,666Apr 21 05:28 PM
MATA NATHAN L.Chief Scientific OfficerApr 17 '26Sale161.631,000161,63013,666Apr 20 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 16 '26Sale160.381,000160,38114,666Apr 20 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 15 '26Sale168.301,000168,29815,666Apr 16 04:15 PM
Nathan L. MataOfficerApr 15 '26Proposed Sale171.9316,6662,865,385Apr 15 05:23 PM
Lin Yu-HsinChief Executive OfficerApr 09 '26Sale181.459,2001,669,339170,934Apr 13 04:15 PM
Chen Wan-ShanDirectorApr 09 '26Sale180.431,100198,4739,096Apr 13 04:15 PM
Chuang Hao-YuanChief Financial OfficerApr 09 '26Sale181.506,2001,125,30393,800Apr 13 04:15 PM
Yu-Hsin LinCEO, ChairmanApr 09 '26Proposed Sale178.73136,00024,307,280Apr 09 04:52 PM
Hao-Yuan ChuangOfficer, DirectorApr 09 '26Proposed Sale178.73100,00017,873,000Apr 09 04:43 PM
Wan Shan ChenaffiliateApr 09 '26Proposed Sale217.7610,1962,220,250Apr 09 12:17 PM
Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
Ph.D.Dr. Yu-Hsin Lin M.B.A.
F.R.M.Mr. Hao-Yuan Chuang C.F.A.
Chief Scientific OfficerDr. Nathan L. Mata Ph.D.
M.D.Dr. Hendrik P.N. Scholl M.A.
Chief Commercial OfficerMs. Kelly Kilpatrick
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)